Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation

• Published in: International journal of radiation oncology, biology, physics Vol. 52; no. 3; p. 806
• Main Authors: Monk, Bradley J, Tewari, Krishnansu S, Puthawala, Ajmel A, Syed, A M Nisar, Haugen, Julie A, Burger, Robert A
• Format: Journal Article
• Language: English
• Published: United States 01-03-2002
• Subjects: Adult; Aged; Brachytherapy - methods; Carcinoma, Endometrioid - mortality; Carcinoma, Endometrioid - radiotherapy; Carcinoma, Endometrioid - secondary; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - radiotherapy; Carcinoma, Squamous Cell - secondary; Female; Humans; Iodine Radioisotopes - therapeutic use; Middle Aged; Ovarian Neoplasms; Retroperitoneal Neoplasms - mortality; Retroperitoneal Neoplasms - radiotherapy; Retroperitoneal Neoplasms - secondary; Retrospective Studies; Uterine Cervical Neoplasms; Vaginal Neoplasms
• ISSN: 0360-3016
• DOI: 10.1016/S0360-3016(01)02728-6

To analyze the outcome of permanent 125I interstitial radiotherapy for unresectable retroperitoneal recurrences of gynecologic malignancies.
A retrospective review of 20 patients treated between 1979 and 1993 was performed to evaluate survival and morbidity associated with the interstitial 125I technique.
Nineteen tumors were located on the lateral pelvic wall and one in the para-aortic region. Eight patients, not previously irradiated, received external beam radiotherapy (EBRT) along with 125I interstitial implants placed at the time of celiotomy. Nineteen (95%) are dead of disease at 1-69 months of follow-up. The median survival was 7.7 months for patients treated with 125I alone and 25.4 months for those treated with both 125I and EBRT. One patient is alive without evidence of disease 69 months after 125I implantation. Fistulas, bowel obstructions, and fatal complications occurred only among patients previously irradiated.
When used in a previously irradiated field, 125I interstitial radiotherapy has major morbidity and is unlikely to be associated with cure or long-term survival. In radiotherapy-naive patients with unresectable isolated recurrent gynecologic malignancies, 125I implants and EBRT are feasible and occasionally may contribute to long-term disease-free survival.